U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

LOS ANGELES, Sept. 21, 2023— Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the“Company”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials